Evaluation of screening for nasopharyngeal carcinoma: trial design using Markov chain models by Chen, H H et al.
High age-standardized incidence rates of nasopharyngeal carci-
noma (NPC), of the order of 15–30 per 100000, have been
reported for several populations including southern China, Hong
Kong, Taiwan, Singapore, and Eskimos in Alaska, Canada and
Greenland (Lanier et al, 1980; Zeng et al, 1985; Muir et al, 1987;
Chen et al, 1988; Lee et al, 1988; Sasco, 1991). In these areas,
NPC is a major cause of cancer death. Since research has shown
that 5-year survival for stage I is 80% compared to only 15% for
stage IV (Sham and Choy, 1990), it could be of considerable
benefit if tumours were detected at an early stage via a screening
regime. However, the ability of screening to identify cases in the
sub-clinical period is dependent on the evolution of the tumour
from biological onset to the manifestation of clinical symptoms.
Epidemiological studies have demonstrated that Epstein–Barr
virus (EBV) is an important aetiological factor for NPC (Henle
and Henle, 1985). Serological surveys have found that NPC is
highly associated with raised titres for a series of EBV antibodies,
high titres of immunoglobulin A (IgA) antibodies to the viral
capsid antigen (VCA) and early antigen (EA) of the virus.
Previous research has shown that these serological markers are
antecedent to the biological onset of tumour cells (Ho, 1978;
Henle and Henle, 1985). Using the serological markers, some
screening regimes have been launched to identify these high risk
groups so as to detect more cases at an early stage of the disease.
Table 1 shows the comparison of the stage distribution between
screened (for IgA antibodies) and non-screened populations, from
the published literature (Zeng et al, 1979, 1980; Zeng, 1985; Zong
et al, 1992). The proportion of stage I and II tumours in the
screened group is higher (68.7%) than in the non-screened (25%)
group. In view of the above, a reasonable screening regime might
be to test a population relatively infrequently for the IgA marker.
Those testing positively might then be subject to clinical examina-
tion, for example indirect mirror examination, at more frequent
intervals and advised to consult a doctor after nose-bleeding
episodes. It should be noted that although indirect mirror examina-
tion is a specialist technique, it may be a reasonable use of
resources in this context, in that it is only used on the minority of
subjects who test positive on the serological marker.
Although the screening programmes referred to above have
indicated that screening can reduce the proportion of advanced
stage NPC, the natural history of NPC has not yet been fully inves-
tigated. Suppose the disease develops by the following process:
1.All individuals begin free of disease.
2.Some individuals enter a specific EBV reactivation state,
manifested by the IgA antibody response to the VCA, putting
these individuals at very high risk of developing NPC.
3.Some of the IgA-positive individuals then enter the preclinical
but screen-detectable phase (PCDP) of NPC, i.e. to NPC
which is asymptomatic but detectable by indirect mirror
examination or endoscopy.
4.The individuals with preclinical NPC then advance at an
unknown rate to the symptomatic clinical phase.
5.A proportion of the clinical cases finally succumb to death
from NPC.
The duration from EBV infection to onset of preclinical NPC is
hereafter defined as the incubation period, and the period between
entry to the screen-detectable phase and entry to the clinical phase
is referred to as the sojourn time. For brevity, we shall refer to the
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EBV reactivation state simply as EBV infection (although strictly
speaking considerably more subjects are EBV infected than those
with the relevant antibody response). It is important for evaluation
of the efficacy of screening to estimate the rates of transition
between the above five states. As the tumour is occult before the
clinical phase, empirical data give at best incomplete information
on the natural history from EBV infection, biological onset of
tumour cells and surfacing to the clinical phase.
In addition, as few studies have reported mortality as the
primary end point and no randomized trials of screening have been
performed, the efficacy of NPC screening still requires definite
confirmation. In 1987, the World Health Organization (WHO)
called for a population-based randomized trial to evaluate the effi-
cacy of NPC screening based on mortality from the disease; this
has not yet been undertaken. The greatest difficulties in evaluating
the efficacy of NPC screening from mortality data are that a long
follow-up period or large sample size are required to achieve suffi-
cient statistical power. Current knowledge does not immediately
suggest an appropriate length of follow-up or sample size. It would
be inadvisable to initiate another NPC screening regime without
prior information on the likely mortality as well as a pre-deter-
mined sample size based on empirical data and a realistic model.
Quantifying the optimum interval between serum screening or
between clinical examinations are other difficult design issues to
be resolved; determination of the intervals is dependent on the
length of the incubation period of EBV infection and on the
preclinical screen-detectable period of NPC.
An important strategy in reducing the duration of follow-up
required is the use of surrogate end points. It is conceivable that
staging of NPC based on the TNM system is a good surrogate end
point for deaths from NPC. It is relatively straightforward to esti-
mate predicted deaths based on stage, using previously observed
empirical survival data. Even if the surrogate measures are not to
be used for the main analyses, they can be used as an aid to design.
In practice we often do not know the exact time of entering a
given phase. If a subject tests seropositive for EBV at a given time,
we only know that the subject entered the EBV infection phase at
some time before then. A multi-state Markov chain model may be
used to model the natural history of NPC in terms of the five stages
listed above (and described more fully under Materials and
Methods). A Markov chain is a process in time which can take a
number of states (in the current example, no disease, EBV infec-
tion but no NPC, preclinical NPC, clinical NPC) and individuals
move from state to state at random points in time but with rates of
transition that are estimable from empirical data (Chen et al,
1997). The major assumption is that if an individual is known to be
in a given state, for example preclinical NPC, at time t, knowledge
of that individual’s history before time t does not add to our predic-
tion of what will happen to that individual thereafter. The advan-
tage of using a Markov chain model is the ability to estimate the
rate of EBV infection and onset of preclinical cancer even if the
exact times to such events are not known.
The aims of this study are to:
1. derive rough estimates of the rate of EBV infection – transition
rates from EBV infection to preclinical cancer (the incubation
period) – and from the screen-detectable phase to the clinical
phase, based on a multi-state Markov chain model;
2. compare the estimated stage distribution of NPC by different
screening frequencies (including an unscreened group) based
on (1);
3. predict mortality based on (2) and on published survival rates
by stage;
4. calculate the required sample size or duration of follow-up
using either NPC mortality or a surrogate for mortality in a
hypothetical randomized trial of NPC screening.
The above strategy illustrates the use of the models on
published data, not to obtain definitive answers to questions of the
efficacy of screening, but to derive approximate prior estimates to
assist in the design of future studies to obtain such answers.
MATERIALS AND METHODS
Definition of the Markov chain model
In order to depict the natural history of NPC a four-state Markov
model is proposed including No disease (0), EBV infection (1),
preclinical screen-detectable phase (2) and clinical phase (3). We
assume that this model is progressive, i.e. no regression from EBV
infection to no EBV infection is possible, with a similar assump-
tion for more serious states. There are three parameters in this
model, l1, l2, l3, representing the rate of EBV infection, the tran-
sition rate from EBV infection to the PCDP and the transition rate
from the PCDP to the clinical phase respectively. This is expressed
as the following transition matrix:
No EBV PCDP Clinical
disease infection NPC NPC
No disease [
–l1 l1 00 ]
EBV infection 0– l2 l2 0
PCDP NPC 00 – l3 l3
Clinical NPC 00 0 0
(1)
Based on (1), the transition probabilities for building up the
likelihood function can be derived, as shown in Appendix 1.
Data for the development of likelihood function
Table 2 shows different transition histories and numbers of
transitions of each type for the studies outlined in Table 1. The
application of the transition probabilities in Appendix 1 to the
corresponding transitions in Table 2 enables us to develop the like-
lihood function for each study to estimate the three parameters.
For example, Zeng et al (1985) found 1118 EBV infections among
20 276 attendants and 18 asymptomatic NPC cases by further indi-
rect mirror examination. The corresponding transition probabili-
ties for no disease, EBV infection and asymptomatic NPC during
time t, say period to age at first screen, are denoted p00(t), p01(t),
and p02(t). The likelihood function based on this can be written as
L(.) = [p00(t)]19590 ´ [p01(t)]1118 ´ [p02(t)]18 (2)
Table 1 The comparison of the stage distribution between screen-detected
and clinically detected based on published data on NPC screening during
1979–1992
Stage I Stage II Stage III Stage IV
Screen-detected 43.2% 25.5% 24.1% 7.2%
Clinically detected 8.4% 16.6% 46.8% 28.1%1896 HH CHen et al
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The likelihood function for other studies may be developed in a
similar way. It should be noted that, although the transition from
the PCDP to clinical NPC is not directly observed, the information
on transitions from no disease to clinical NPC from Zong et al
(1992) allows us to estimate this parameter, l3.
The method used for estimation of the parameters was a quasi-
likelihood approach equating the observed numbers of transitions
with the expected, using a non-linear regression model. Details of
this method are given by Duffy et al (1995) and Chen et al (1996).
Since the data used in this study were from published accounts of
various studies, we estimated the transition parameters for each
study separately, then calculated weighted averages over all
studies, weighting for each study by the numbers of participants.
The pooled estimates were then used to predict cases and deaths
from NPC.
The transition probabilities from equation (2) were used to
calculate predicted EBV-positive and NPC cases detected by
screen (screen-detected) or diagnosed between screens (interval
cancers) for various screening regimes.
RESULTS
Parameter estimation
Table 3 shows estimated results for three parameters, l1 (no
disease to EBV infection), l2 (EBV infection to PCDP) and l3
(PCDP to clinical phase), for each study. The estimated weighted
average instantaneous transition rates were 0.00075, 0.002819 and
0.32583 for l1, l2 and l3 respectively. Since only one study in
Table 2 provided data on symptomatic NPC, the estimate of l3 is
based on this study only (Zong et al, 1992).
The parameter estimates in Table 3 indicate an annual rate of
EBV infection of just under 1 per 1000, and an annual rate of
progression to preclinical NPC in EBV-positive subjects of around
3 per 1000. The inverse of l3 in Table 3 estimated the mean
sojourn time (the average time period spent in the preclinical
phase) as approximately 3.1 years.
Application: prediction of NPC cases and deaths based
on the incidence rate in Hong Kong
We have estimated the parameters for transition from no disease to
EBV infection, from EBV infection to the PCDP and from the
PCDP to the clinical phase. We apply these estimates to calculate
the predicted number of EBV infections, preclinical NPC cases
detected by screening PCDP and clinical NPC cases for a hypo-
thetically screened population from Hong Kong.
Since the EBV infection rate obtained from the present study
was not based on the Hong Kong population, the underlying EBV
infection rate is adjusted to yield NPC rates that are representative
of the Hong Kong population. Since no studies have so far
reported the exact underlying EBV infection rate for Hong Kong
we used an indirect method to adapt the underlying rate. We first
calculate an age-specific cumulative incidence rate based on the
present parameters, and adjusted l1 to give the corresponding
cumulative incidence rate for Hong Kong calculated using data
from Cancer Incidence in Five Continents (Muir et al, 1987). We
use the male population, which has a particularly high incidence of
NPC. The prevalence of EBV infection was estimated as 17.218%
in Hong Kong males. The estimated incidence rate of NPC in the
age group 40–69 was 74.4 per 100 000, which is consistent with
the figure of 76.6 per 100 000 from Cancer Incidence in Five
Continents.
We present predicted results for four screening regimes in a
hypothetical population of 100 000 Hong Kong Chinese males.
The four regimes are:
1. Three-yearly IgA/VCA plus annual indirect mirror
examination.
2. Three-yearly IgA/VCA plus 3-yearly indirect mirror
examination.
3. Six-yearly IgA/VCA plus annual indirect mirror examination.
4. Six-yearly IgA/VCA plus 3-yearly indirect mirror
examination.
Table 2 Numbers of possible types of transition for NPC based on Markov model (1) by studies from 1980 to 1992
Types of transition
No disease No disease No disease No disease
Studies ® No disease ® EBV infection ® Preclinical NPC ® Clinical NPC
(0 ® 0) (0 ® 1) (0 ® 2) (0 ® 3)
Zeng et al (1985) 19 590 1118 18 –
Zeng (1985) 15 173 144 7 –
Zong et al (1992) (a) Screened:
39 225 2792 31 –
(b) Control:
397 000 – – 140
Zeng et al (1979, 1980) 144 496 405 55 –
Table 3 Estimated parameters for NPC based on Markov model (1)
l1: l2: l3:
No disease EBV infection Preclinical NPC
® EBV infection ® Preclinical NPC ® Clinical NPC
Studies (0 ® 1) (1 ® 2) (2 ® 3)
Zeng et al (1985) 0.0009394 0.0005288 –
Zeng (1985) 0.00018 0.00173 –
Zong et al (1992) 0.00117 0.0051 0.3258
Zeng et al
(1979, 1980) 0.00043 0.0005697 –
Weighted average 0.00075 0.002819 0.3258Evaluation of screening for nasopharyngeal carcinoma 1897
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Table 4 shows the predicted EBV-positive and NPC cases for
the four screening regimes. The proportion of interval NPC cases
expected for screening regimes (1) three-yearly IgA/VCA plus
annual indirect mirror examination, and (2) three-yearly IgA/VCA
plus three-yearly indirect mirror examination, were 0.1 and 0.25
respectively. This yielded 59% [0.25–0.1]/0.25) for the prevented
fraction of interval NPC cases due to changing from 3-yearly to 1-
yearly indirect mirror examination under 3-yearly IgA/VCA. As
the difference between 3-yearly and 6-yearly IgA/VCA was not
substantial, a similar prevented fraction was observed for
screening regime (3) and (4), which was based on 6-yearly
screening for IgA/VCA.
From the results in Table 4, we use the proportions in Table 1 of
screen-detected and clinically detected tumours by stage to predict
the incidence by stage. Stage-specific 5-year survival is given by
published literature (Sham and Choy, 1990; Sasco, 1991) as 80%,
69%, 42% and 15% for stages I to stage IV respectively. These
were then applied to the stage distributions to give expected 5-year
deaths from NPC by screening regime. Results are shown in Table
5 for 3-yearly and 6-yearly serological testing.
With 3-yearly serum screening, one would expect annual
indirect mirror examination to reduce 5-year mortality by 33%,
and 3-yearly indirect mirror examination to lead to a 28% reduc-
tion. With 6-year serum screening, the results are almost exactly
the same. Thus, the frequency of indirect mirror examinations
between serum screens has a greater bearing on the expected
mortality than the frequency of serum testing.
DISCUSSION
In this study, we have estimated 33% and 28% reductions in
mortality from NPC attributed to intensive indirect mirror exami-
nation of IgA/VCA-positive subjects for annual vs no screening,
and 3-yearly vs no screening, by applying a Markov chain model
to the published results for NPC mass screening to estimate the
relevant parameters. The difference in the proportion of screen-
detected and clinically detected cancers between 3-yearly and 6-
yearly IgA/VCA screening was not substantial. This suggests that
6-yearly serological marker screening plus annual indirect mirror
examination can reduce the mortality from NPC by approximately
30%. From the cost-effectiveness viewpoint, it might be argued
that 6-yearly IgA/VCA for NPC, in combination with 3-yearly
indirect mirror examination, might be sufficient.
While these results cannot be regarded as strong evidence of a
mortality benefit, they give a useful estimate of the size of likely
benefit and indicate the regime of choice if a genuine trial were
proposed. While the published literature does not give data in
sufficient detail to assess the fit of our models, the results suggest
reasonable design strategies for a population-based trial of NPC
screening. Such a trial, however, in addition to the primary
purpose of evaluating the effect of the screening, would also
provide diagnostics for the models.
To simplify the calculations, we estimated the distribution of stage
from previously published stage distributions, rather than directly
estimating transition rates between stages. It could be argued that one
can use a six-state Markov chain model to estimate these parameters,
as used by Chen et al (1997) for modelling breast cancer progression.
The major resource available for such estimation is the stage data
from prevalence screening in the published literature, as shown in
Table 6. The detailed algebra and calculations to estimate progression
rates from these data are given in Appendix 2.
Table 4 Predicted numbers of IgA positive cases and nasopharyngeal
carcinoma in males by annual and 3-yearly NPC screening regimes in
conjunction with 3-yearly and 6-yearly IgA screening programmes based on
the Hong Kong incidence rate with n = 100 000, and assuming 100%
sensitivity for IgA screening
Three-year IgA  Six-year IgA
screening screening
Clinical assessment Clinical assessment
Diagnostic group One-year Three-year One-year Three-year
Total serum IgA (+) 19020.9 19020.9 19013.1 19013.1
Total screen-detected 400.5 336.6 397.1 334.9
NPC
Interval cancers after 2.0 2.0 6.5 6.5
negative Serum IgA
Interval cancers after 43.5 107.4 42.3 104.6
negative clinical assessment
Total interval cancers 45.5 109.4 48.9 111.2
Total NPC cases 446 446 446 446
Table 5 Stage distribution and predicted 5-year deaths from NPC for indirect mirror examination frequencies of 1 year and 3 years, under 3-yearly and
6-yearly serum IgA testing, and for no screening at all
Serum IgA testing Indirect mirror
Stage
frequency examination Outcome I II III IV Total
3-yearly 3-yearly Cancers 155 104 132 55 446
Deaths 31 32 77 47 187
1-yearly Cancers 177 110 118 41 446
Deaths 35 34 68 35 172
No screening Cancers 38 74 209 125 446
Deaths 8 23 121 106 258
6-yearly 3-yearly Cancers 154 104 133 55 446
Deaths 31 32 77 47 187
1-yearly Cancers 176 109 119 42 446
Deaths 35 34 69 36 174
No screening Cancers 38 74 209 125 446
Deaths 8 23 121 106 2581898 HH CHen et al
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Using the methods in Appendix 2, the transition rates from stage
I to stage II and from stage II to stage III+ within the PCDP were
estimated as 0.06055 and 0.05054. Transition rates from preclin-
ical stage I to clinical stage I, and preclinical stage II+ to clinical
stage II+, were estimated as 0.011445 and 1.72 respectively. Based
on these parameters, we calculated the expected proportion of
stage I cancers by different detection modes. Detailed calculations
are given in Appendix 3. For the prevalent screen, we estimated
that approximately 45% of cases would be stage I tumours. This is
very close to the figure for screen-detected cases in Table 1 based
on the published literature. For cases after negative IgA screening,
a 6-year regime of IgA screening gave 16% stage I clinical cases
during 6 years. This is consistent with the figure for clinically
detected cases in Table 1. For incident screens, annual and 3-
yearly screening regimes of clinical assessment yielded 98% and
94% of screen-detected cases being in stage I. For interval cancers,
the estimated proportions of stage I tumours for annual and 3-
yearly clinical assessment were 37% and 23% respectively.
The predicted mortality estimated in this study can be applied to
calculate power for a randomized trial that might be launched in
the future. The use of surrogate end points for deaths from NPC,
such as stage distribution, could also be considered. We calculated
the required sample size for surrogate end points based on Day and
Duffy’s method (1996) which was used in their paper to calculate
sample size for different frequencies of breast cancer screening.
The formulae for the power calculations for both a mortality end
point and a surrogate end point are shown in Appendix 4.
To calculate power for a possible trial in Hong Kong, we use the
estimates of 33% and 28% reduction in mortality from NPC attrib-
uted to screening for annual and 3-yearly regimes as compared to no
screening. These come from the pragmatic estimates using the stage
distributions from the literature and the simple four-state model in
equation (1), in view of the fact that these are largely in agreement
with estimates from the more sophisticated and complex models of
Appendices 2 and 3. We assume two serum IgA tests 6 years apart,
with annual or 3-yearly clinical assessment of those screened IgA-
positive, i.e. a 6-year screening phase of the trial, with seven or three
rounds of clinical assessment. Suppose each arm has 50 000 subjects
with 76.6 per 100 000 incidence rate, that of Hong Kong males aged
40–69. Assume an average of 5 years follow-up for survival of the
NPC cases. The variances for mortality and surrogate end point for
annual screening versus no screening were calculated as 0.0187 and
0.0083, respectively, according to Table 7 and expression (A-5) and
(A-6) in Appendix 4. With 50 000 subjects on each arm and
two-sided significance testing at 5% level, a trial based on actual
mortality would have 82% power for a comparison of annual
clinical examination with no screening, and 69% power for a
comparison of 3-yearly clinical examination with no screening. The
corresponding power estimates using the surrogate end point of
predicted deaths from stage would be 99% and 89%.
Since there is, as yet, no randomized trial evidence on the effect
of screening for NPC, it is arguably necessary for a future trial to
be based on actual mortality. For such a trial to have high sensi-
tivity, very large sample sizes are needed. With annual clinical
examination, a 5% significance level and two-sided testing, 61 000
persons per arm will be required for 90% power. With 3-yearly
clinical examination, 87 000 per arm would be needed.
In conclusion, a Markov chain model was developed, based on
limited published data, to estimate relevant parameters to predict
the mortality reduction to be expected by screening for NPC. The
application of these parameters to a population with a relatively
high incidence rate yields support for the efficacy of 6-yearly sero-
logic screening followed by more frequent clinical assessment
(indirect mirror examination) of those who are seropositive.
Annual and 3-yearly indirect examination might be expected to
reduce the number of deaths from NPC by 33% and 28%.
Prediction of deaths from these models can aid design of a future
randomized trial in a high incidence area such as Hong Kong.
Table 6 Numbers of possible types of stage transition for NPC based on Markov model (2) by studies from 1980 to 1992
Types of transition
No disease No disease No disease No disease
®® ® ®
Studies no disease Stage I Stage II Stage III+
(0 ® 0) (0 ® 1) (0 ® 2) (0 ® 3)
Zeng et al (1979, 1980) 147 974 12 19 23
Zeng et al (1985) 20 708 10 6 2
Zong et al (1992)  42 007 28 5 8
Table 7 Stage distribution and calculation of variance components for mortality and surrogate endpoint by different screening regime
1-year 3-yearly No clinical 5-year
Stage clinical assessment clinical assessment assessment death rate
(qi1)( qi3)( qi0)( Pi)
I 0.3964 0.3466 0.0843 0.20
II 0.2462 0.3333 0.1664 0.31
II 0.3964 0.2964 0.4683 0.58
IV 0.0933 0.1231 0.2810 0.85
1/SPq 2.57 2.38 1.73
SP2q/(SPq)2 1.30 1.28 1.14Evaluation of screening for nasopharyngeal carcinoma 1899
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Appendix 1
The formulae for transition probabilities for expression (2) in text
are:
Appendix 2
The transition matrix for a stage model would be:
Estimation of parameter g4 and g5 in text was performed by first
estimating the transition rates for progression in the more complex
model involving preclinical disease at stages I, II and III+. We
therefore estimated the following transition rates:
m1: Preclinical stage I to preclinical stage II
m2: Preclinical stage II to preclinical stage III+
v1: Preclinical stage I to clinical stage I
v2: Preclinical stage II to clinical stage II
v3: Preclinical stage III+ to clinical stage III+.
Using the methods of Chen et al (1997) and the data in Table 6,
m1 and m2 were estimated as 0.06055 and 0.05054. In conjunction
with sojourn time and the proportion of clinical stage 1 tumours, v1
was back-calculated by the following:
No EBV
Preclinical Clinical
disease Infection Stage I Stage II+ Stage I Stage II+
No disease –g1 g1 00 00
EBV 0– g2 g2 00 0
infection
Preclinical
Stage I 00 – ( g3 + g4) g3 g4 0
Stage II+ 000 – g5 0 g5
Clinical
Stage I 0000 00
Stage II+ 0000 00 [ ]
(A-1)
(A-2)1900 HH CHen et al
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Substitution of m1 = 0.06055 and l3 = 0.32583 (Table 3) and
t = 3.1 years give v1 as 0.011445.
Similarly, the estimate of v2 was back-calculated by the
following expression:
Substitution as for (A-2) and m2 = 0.0504 gives v2 as 0.31291.
As the proportion of stage II+ cancers among clinical cases is high,
the mean duration from preclinical to clinical stage II+, i.e. 1/ v3,
must be very short, and can be regarded as approximately zero in
years. Instead of using stage II and stage III+, we calculate the
expected time spent in preclinical stage II+ before moving to the
clinical phase as the weighted average of the times to clinical
disease from preclinical stage II and III+ to clinical stage II and
III+, according to the proportion of clinical tumours in stage II and
III+ from Table 1. We then invert the expected length of time in
preclinical stage II+ to give the transition rate to clinical disease as:
(1/v2 (16.64/91.57)+0(74.93/91.57))–1 = 1.72
Appendix 3
Estimation of the proportion of stage I tumours by detection mode
is as follows:
(1) Prevalent screen
Given the parameters in Appendix 2, the proportion of stage I
tumours at the prevalent screen for a population 50 years of age on
average was calculated according to the following expression:
This yields 45.10% stage I among prevalent NPC cancers.
(2) Incident screen
A similar calculation was performed to estimate the proportion of
stage I cancers for incident screens by substituting screening
interval for age.
(3) Interval cancers
The expression for the proportion of stage 1 cases among interval
cancers is:
Appendix 4
Power calculations can be performed as follows.
For annual screening versus no screening, for example, suppose
screening was annually applied to a hypothetical population with
an incidence rate of NPC of 76.6 per 100 000 for 6 years.
According to Day and Duffy’s method (1996), the variance for the
mortality end point is:
and for the surrogate endpoint, the variance is
where Pi is the probability of death from NPC for an individual in
category i of the surrogate end point (stage in our case); qi1 and qi0
are the probability of being in category i in each arm j, j = 0 (no
screening) and 1 (annual screening); and N is the number of
individuals on each arm of the trial.
Suppose the estimated reduction in mortality from NPC was
estimated as T1/T0, where T1 =  SPiqi1 and T2=SPiqqi0. Power,
denoted by 1-b, for a test at significance level a (two-sided), can
be calculated as:
1-b = j (–Z-log(T1/T0)/S)
where Z is the upper (1–0.5a) point of the standard normal distrib-
ution, j is the standard normal distribution function and S is the
square root of Vobs or  Vpred, depending on whether observed






E (p2 = clinical stage 2) =